"Metastasis-associated MCL1 and P16 copy number alterations dictate resistance to vemurafenib in a BRAFV600E patient-derived papillary thyroid carcinoma preclinical model" by Mark Duquette

Article

Metastasis-associated MCL1 and P16 copy number alterations dictate resistance to vemurafenib in a BRAFV600E patient-derived papillary thyroid carcinoma preclinical model

Oncotarget (2015)

Mark Duquette, Harvard University
Peter M. Sadow, Harvard University
Amjad Husain, Harvard University
Jennifer N. Sims, Harvard University
Zeus A. Antonello, Harvard University
Andrew H. Fischer, University of Massachusetts Medical School
Chen Song, Harvard University
Elena Castellanos-Rizaldos, Harvard University
G. Mike Makrigiorgos, Harvard University
Junichi Kurebayashi, Kawasaki Medical School
Vania Nose, Harvard University
Paul Van Hummelen, Harvard University
Roderick T. Bronson, Harvard University
Michelle Vinco, University of Michigan
Thomas J. Giordano, University of Michigan
Dora Dias-Santagata, Harvard University
Pier Paolo Pandolfi, Harvard University
Carmelo Nucera, Harvard University

Link

Disciplines

Publication Date

December 15, 2015

DOI

10.18632/oncotarget.6442

Citation Information

Mark Duquette, Peter M. Sadow, Amjad Husain, Jennifer N. Sims, et al.. "Metastasis-associated MCL1 and P16 copy number alterations dictate resistance to vemurafenib in a BRAFV600E patient-derived papillary thyroid carcinoma preclinical model" Oncotarget Vol. 6 Iss. 40 (2015) p. 42445 - 42467
Available at: http://works.bepress.com/zeus-antonello/5/